Life sciences company Cytiva Monday said it has acquired Vanrx Pharmasystems, a Canadian developer of robotic aseptic filling machines to fill vials, syringes, and cartridges with reduced risk and increased speed to patients.
Vanrx manufactures safe and cost-effective injectable therapies. Cytiva said the Vanrx portfolio complements its manufacturing capacity solutions.
Vanrx's flagship products are the SA25 Aseptic Filling Workcell and Microcell Vial Filler, which automate aseptic filling using robotics within closed, gloveless isolators.
Vanrx will enhance Cytiva FlexFactory platforms and KUBio modular facilities, enabling it to accelerate biomanufacturing from start to finish.
This is the first acquisition by Cytiva, which became a Danaher operating company in April 2020.
Vanrx was founded in 2007 by Chris Procyshyn and Ross Gold and currently has over 120 associates. All these employees have been offered employment with Cytiva.
Olivier Loeillot, Vice President and Head of BioProcess, Cytiva, said, "Cytiva becomes the first 'idea to injection' biotechnology company by bringing Vanrx into our already strong portfolio. From drug development, through drug substance and now into drug product, we can help biomanufacturers bring their therapies to patients faster."
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.